Overview

A Phase II Open Label, Umbrella Study

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Fulvestrant
Olaparib